Compass Diversified Holdings

Q2 2024 Earnings Conference Call

7/31/2024

spk02: Good afternoon, and welcome to Compass Diversified's second quarter 2024 conference call. Today's call is being recorded. All lines have been placed on mute. If you would like to ask a question, at the end of the prepared remarks, please press star 1-1 on your touchtone telephone. At this time, I would like to turn the conference over to Cody Slaw of Gateway Group for introductions and the reading of the safe harbor statement. Please go ahead, sir.
spk04: Thank you, and welcome to Compass Diversified second quarter 2024 conference call. Representing the company today are Elias Szabo, Cody's CEO, Ryan Falkingham, Cody's CFO, and Pat Massarello, COO of Compass Group Management. Before we begin, I'd like to point out that the Q2 2024 press release, including the financial tables and non-GAAP financial measure reconciliations for subsidiary adjusted EBITDA, adjusted EBITDA, adjusted earnings, and pro forma net sales are available at the investor relations section on the company's website at compassdiversified.com. The company also filed its Form 10-Q with the SEC today after the market closed, which includes reconciliations of certain non-GAAP financial measures discussed on this call and is also available at the investor relations section of the company's website. Please note that references to EBITDA in the following discussions refer to adjusted EBITDA as reconciled to net income or loss from continuing operations in the company's financial filings. The company does not provide a reconciliation of its full year expected 2024 adjusted earnings, adjusted EBITDA, or subsidiary adjusted EBITDA because certain significant reconciling information is not available without unreasonable efforts. Throughout this call, we will refer to Compass Diversified as COTI or the company. Now allow me to read the following safe harbor statement. During this conference call, we may make certain forward-looking statements, including statements with regard to the expectations related to the future performance of COTI and its subsidiaries, the impact and expected timing of acquisitions and divestitures, and future operational plans, such as ESG initiatives. Words such as believes, expects, anticipates, plans, projects, should, and future or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ on a material basis from those projected in these forward-looking statements, and some of these factors are enumerated in the risk factor discussion in the Form 10-K as filed with the SEC for the year ended December 31st, 2023, as well as in other SEC filings. In particular, the domestic and global economic environment supply chain, labor disruptions, inflation, and changing interest rates all may have a significant impact on Cody and our subsidiary companies. Except as required by law, Cody undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. At this time, I would like to turn the call over to Elias Sabo.
spk05: Good afternoon, everyone, and thanks for joining us today. I am pleased to report yet another strong quarter of results. Continuing to execute our strategy of owning a growing number of innovative, disruptive, and high-growth businesses meant we performed exceptionally well in the second quarter, even against the backdrop of a slowing economy. While the current business environment has had a negative impact on our industrial businesses, our branded consumer vertical performed extremely well this quarter. led by BOA, Primaloft, and Lugano, the strong performance of our consumer vertical more than offset any weakness we saw in our industrial businesses. As we predicted in Q1, inventory destocking headwinds subsided this past quarter, and because of this, BOA had another great quarter, and Primaloft returned to double-digit growth. We believe both businesses are positioned for a strong back half of the year. In addition, Lugano continued its trend of remarkable growth. Last quarter, we opened our first international salon in London, and in just a few short months, like many of our Lugano salons, it has vastly exceeded our expectations. Combined, Lugano, BOA, and Primaloft represent approximately half of our EBITDA. With all three of these businesses performing so well this past quarter, and with them positioned so strongly for the rest of the year, we are feeling bullish about the second half of 2024 and beyond. As I mentioned earlier, despite our overall outperformance this quarter, a weakening global macro economy made for a challenging quarter for our industrial businesses. Our industrial vertical saw a decline in both revenues and adjusted EBITDA in Q2. We believe this somewhat muted performance will continue through the rest of the year. However, we remain confident in the overall positioning of this vertical, and we believe it is well positioned for a strong 2025. All in all, it was another great quarter for Cody and one that further demonstrated the power of our long-term strategy. By owning a group of non-correlated, high-growth, innovative businesses, we not only smoothed Cody's overall performance period to period, but in any given period, are more likely to benefit from one or more of our businesses experiencing a true step change in growth. This is the story of diversified growth engines, as evidenced this quarter when we grew by almost 20% year over year. Ryan will go into detail on our financial outlook shortly, but I'd like to briefly discuss our decision to leave our outlook unchanged. We still anticipate we will hit the high end of our consolidated guidance ranges. However, we are not raising our guidance range at this point out of an abundance of caution regarding the weakening economy and a concern for the short-term performance of our three industrial businesses. But overall, we remain really positive about the rest of the year. As Ryan will detail shortly, within our overall outlook, we are shifting some of our adjusted EBITDA expectations from our industrial vertical to our consumer vertical. Even though our overall guidance is staying holistically the same, we believe this mixed shift that favors our faster growing, more protected, and highest valued businesses creates an accelerated level of intrinsic value creation for our stakeholders now and positions us to drive significant growth into 2025 and beyond. With that, I will now turn the call over to Pat. Thanks, Elias.
spk10: As a reminder, throughout this presentation, when we discuss pro forma results, it will be as if we own the Honeypot Company as of January 1st, 2023. I am pleased to report on another successful quarter. On a combined basis, pro forma revenue and adjusted EBITDA grew by 6% and 18%, respectively. On a year-to-date basis, pro forma revenue and adjusted EBITDA increased by 4.9% and 16.6%, respectively, versus year-to-date June 2023. Though Lugano continues to be the largest driver of growth, We saw a broadening of strength with very good performance at both BOA and Primal off this quarter. As Elias touched on, we believe all three of these businesses are well positioned for growth in the remainder of the year and beyond. Within our industrial segment, for the year-to-date period, revenues decreased by 6.7% and adjusted EBITDA decreased by 8% versus year-to-date June 2023. This decline was primarily driven by weak performance at Altor, which declined meaningfully in Q2. The decline was driven by a combination of reduced customer demand in some accounts and churn at a couple of our cold chain distribution partners. Though disappointing, the sales funnel at Altor remains robust and has almost tripled in size since this time last year. New contracts typically take some time to design and test, however, leading to a potentially muted second half of 2024. As a reminder, the company now has what we believe to be a world-class management team in place, and as a result, we are confident the company will rebound in 2025. Arnold continued to grow revenue in the quarter, though once again experienced higher SG&A as we began to modify our manufacturing footprint in an effort to improve efficiencies and grow technological capabilities. As part of this strategic relocation, we anticipate several million dollars in one-time expenses will be incurred over the next few quarters. In addition, we expect $10 to $15 million in one-time capital expenditures as part of this project as we make our way through this transition. Sterno once again grew EBITDA modestly in the quarter as slightly softer sales and the company's food service division were more than offset by strong execution throughout the business. Turning to our consumer segment, for the year-to-date June 2024 period, pro forma revenues increased by 10.9%, and pro forma adjusted EBITDA increased by almost 27% versus year-to-date June 2023. Lugano remained the strongest performer both in the quarter and on a year-to-date basis. Our London salon significantly exceeded expectations during its first quarter of operation, and we continue to see strong performance in Aspen, Palm Beach, and Newport Beach. We're in the process of finalizing the location of our ninth salon, and look forward to sharing its location with you likely on our next quarterly call. We expect Lugano's extraordinary growth to continue throughout the rest of this year and into 2025. I'm also very pleased to report on the acceleration of BOA this in the quarter and prime loss return to growth in the period. For the second quarter, BOA grew revenue by 42.1% and adjusted EBITDA grew by almost 60% versus Q2 2023. The BOA brand saw growth in each of its industry verticals. Similarly, Primaloft grew revenue in EBITDA by 14.1% and 11.1%, respectively, as inventory headwinds in many of its apparel categories continue to abate as expected. We are encouraged by the performance of both Primaloft and BOA this quarter and by their prospects for the rest of the year. Turning to the Honey Pot Company, both for the quarter and for the year-to-date period, Honeypot declined slightly in both revenue and EBITDA versus the same periods in 2023. We purchased the company with the knowledge that Honeypot was losing a small number of non-core SKUs at one of its large national retailers. The short-term impact was slightly greater than our expectations, and as a result, Honeypot's financial performance has been slightly below our expectations for the year-to-date period. The company continues to add new retail and online accounts, however, and we remain confident in the long-term, mission-driven trajectory of the business. Lastly, on 5-11, 2024 represents somewhat of a transition year for the business, given the previously announced leadership changes, lingering inventory-related issues in DTC, and the challenging PFAS transition. As a result, financial performance was somewhat muted in both the quarter and year-to-date period. However, demand for the brand this year, particularly in the professional side, remains robust. While we see financial performance in the remainder of 2024 looking similar to performance in the year-ago period, we continue to expect strong growth in 2025 and beyond following resolution of these exogenous issues facing the business. As a whole, we are very pleased with the first half and remain confident in our outlook for the full year. I will now turn the call over to Ryan for additional comments on our financial results.
spk09: Thank you, Pat. Moving to our consolidated financial results for the quarter ended June 30th, 2024, I will limit my comments largely to the overall results for Cody since the individual subsidiary results are detailed in our form 10Q that was filed to the SEC earlier today. On a consolidated basis, revenue for the quarter ended June 30th, 2024 was $542.6 million, up 11% compared to $486.9 million for the prior year period. This increase was primarily a result of the acquisition of the Honeypot Company and strong growth at Lugano, BOA, and Primaloft, which was partially offset by lower revenue at Altor, 511, and at Velocity as a result of the sale of its Crossman division. Consolidated net loss for the second quarter of 2024 was $13.7 million compared to net income of $17.1 million in the prior year. The second quarter of 2024 included a loss on the sale of Crossman, of $24.6 million, as well as a $7.3 million tax expense recorded at velocity related to evaluation allowance on its deferred tax assets. Adjusted EBIT on the second quarter was $105.4 million, up 27% compared to $82.9 million in the prior year. The increase was due to the acquisition of the Honeypot Company and strong growth at Lugano, BOA, and Primaloft. Included in adjusted EBITDA in the second quarters of 2024 and 2023 were management fees and corporate costs of $21 million and $19.3 million respectively. Adjusted earnings for the second quarter were above our expectations, coming in at $39.8 million. This was up significantly from $29.2 million in the prior year quarter due to strong performances at Lugana and BOA. Now moving to our 2024 guidance. As a result of our financial performance in the second quarter, our expectations for the remainder of 2024, and our current view of the economy, we are maintaining our 2024 outlook. Thus, our full year 2024 subsidiary adjusted EBITDA is consistent with what we provided on our last earnings call of between $480 million to $520 million. Given the outperformance of our branded consumer companies, we are increasing the subsidiary adjusted EBITDA range for our branded consumer vertical by $10 million to $365 million to $395 million. However, we are reducing the subsidiary adjusted EBITDA range for our industrial vertical also by $10 million to $115 million to $125 million. We expect full-year 2024 adjusted EBITDA to be between $390 million and $430 million, consistent with what we provided on our last earnings call. This range factors in an expected $86 million in corporate level overhead and management fees in 2024. This compares to $341 million in adjusted EBITDA in 2023. Finally, we are maintaining our full year 2024 adjusted earnings guidance range of between $148 million and $163 million, and we expect the remaining six months of adjusted earnings to be slightly more skewed toward the fourth quarter. turning to our balance sheet. As of June 30, 2024, we had approximately $68.4 million in cash, approximately $544 million available on our revolver, and our total leverage ratio was 3.72 times. Our leverage ratio at the end of the quarter declined, as anticipated, as a result of our strong operating performance. Absent any significant acquisitions for the remainder of 2024, we expect our total leverage ratio to continue to decline. We have substantial liquidity, and as previously communicated, we have the ability to upsize our revolver capacity by an additional $250 million. With our liquidity and capital, we stand ready and able to provide our subsidiaries with the financial support they need, invest in subsidiary growth opportunities, and act on compelling acquisition opportunities as they present themselves. Turning now to cash flow provided by operations. During the second quarter of 2024, We used $35 million of consolidated cash flow from operations. Lugano used $71 million in cash flow from operations to support its continued extraordinary growth. Outside of Lugano, the other nine subsidiaries combined produced $36 million in cash flow from operations in the second quarter, allowing us to reduce our leverage as stated earlier. And finally, turning to capital expenditures. During the second quarter of 2024, we incurred $11.2 million of CapEx at our existing subsidiaries compared to $13.7 million in the prior year period. The decrease was primarily a result of a decline in 511 store rollouts in 2024. For the full year of 2024, we anticipate total capital expenditures of between $55 million and $65 million. We continue to see strong returns on invested capital at several of our growth subsidiaries and believe they will have short payback periods. Capital expenditures for the remainder of 2024 will primarily be at Lugano for new retail salons and at Arnold, as previously discussed by Pat. With that, I will now turn the call back over to Elias.
spk05: Thank you, Ryan. Before moving to the Q&A portion of the call, I'd like to briefly discuss both our ESG strategy and the current M&A market. As we have told you before, our business model is designed to foster the long-term development and growth of our subsidiaries. We are not constrained by short investment horizons, and our permanent capital base allows us to take a long-term view. This approach is vital because meaningful innovation and industry disruption both require time and they also require an exceptional talent pool. The future thinking for people and planet pillar of our ESG strategy prioritizes attracting the best people and focusing on their professional development and holistic wellbeing. Additionally, our commitment to diversity and inclusion enriches our teams with a variety of perspectives and experiences. We have integrated these principles into our business model so that we can attract and keep people who are not only really good at what they do, but who will also join us in taking bold steps, pushing boundaries, and creating lasting value for our stakeholders. Turning to the M&A market, while there has been an uptick in deals recently compared to what we've seen in years past, We have not returned to historic activity levels, and recent deal quality hasn't met our standards. We remain steadfast in our efforts to identify, own, and actively manage innovative, high-growth companies. We also believe our competitive edge will shine in today's high interest rate landscape. When debt markets are weak for single asset buyouts, our permanent capital competitive advantage only grows. As Ryan mentioned, our strong liquidity position also enables us to act on acquisition opportunities and to invest in our subsidiaries to build upon our track record of delivering growth into 2025 and beyond. With that, operator, please open the lines for Q&A.
spk02: Thank you. As a reminder, if you would like to ask a question, please press star 11 on your telephone. We also ask that you wait for your name and company to be announced and your line opened before you proceed with your question. Our first question today comes from Larry, Susan Solo of CJS Securities. Your line is open.
spk06: Great. Thanks. Thanks, and good afternoon. I guess two questions, one operating and one just on the M&A environment. It sounds like BOA had a really nice quarter, really good to see. Maybe give us a little more color on the strength. Is it just the deciding of inventory, the stocking? Is BOA the primary driver of the $10 million increase on the branded side?
spk10: Certainly one of them, Larry. This is Pat. How are you? Good. You know, it was really broad breadth, as I mentioned, across each of the BOA verticals. I would say the company is developing a great business in workwear and it's becoming a more material part of their business. And that was certainly a driver of growth here as well, both domestically and internationally.
spk05: Yeah, with respect to the 10 million driver of growth, Larry, I would say is sort of a combination. Primaloft, you know, bounced back and exceeded our expectations, as did BOA. The numbers BOA put up were really extraordinary. And, you know, as you know, this has, you know, been one of the better performing businesses that we've owned prior to the inventory destocking. So it's really good to see that behind them and get back on, you know, kind of a normal growth trajectory. And then, of course, Lugano continues just to, you know, grow at a remarkable level. And so those three together, and, you know, as I said, they roughly, you know, represent half of our EBITDA. Having them be growing like they are right now, that kind of enables us to up our expectations significantly. in the back half of the year by, you know, for the full year by $10 million on the consumer side.
spk06: And just on the honeypot, a little bit, you know, below expectations, you called out some of it, you know, it sounds like you thought some of it, you were going to lose some of these SKUs. Is it also some traffic at these bigger box retail stores, you know, one in particular, and is that still, you know, the big box still the majority of your revenue? Yeah.
spk10: Uh, yeah, those, a couple of the bigger box stores are close to half of our revenue or slightly more than that probably are a good chunk of our revenue. Um, and I would say there is some well publicized, uh, traffic reductions that at least one of those, um, that would come into account.
spk06: Fair enough. Okay. Just, just last on the acquisition environment. Um, just curious, you know, obviously multiples haven't really come down and I know, you know, in the healthcare particular, I'm just curious your thoughts, no timetable. And I'm sure you've, uh, Kurt's a good man, so I'm sure you repurposed him in doing a lot of good stuff behind the scenes there. But I'm curious, are you expanding your horizons a little bit around healthcare? Again, just any thoughts on potential investments in that vertical specifically? Thanks.
spk05: Yeah, Larry, I would say just in general in the M&A market, there is increased deal volume, as I mentioned, but we're really kind of focused on making sure that companies are are very innovative in what they do today and the products and the margins they can enjoy from that, but then have a source of continuing innovation to be able to continue and enjoy that. And I would say that really narrows down the target opportunities pretty significantly of what we will go after. Unfortunately, broadly in the market, we haven't seen those really premium companies coming to market yet. But I think that probably there's some green shoots and that the market is recovering. In terms of healthcare in particular, and by the way, this goes across great consumer and great industrial. When you see an A or an A-plus business, which are the kind of businesses that we look for, these things are trade. They always trade at premium multiples because they don't trade in compromised times typically. And so, you know, our expectation is when these businesses come, we're going to have to pay a clearing multiple. It kind of gets circular back to the fact that we're just not seeing a lot of them out there. With respect to healthcare, We are opening the parameters a little bit. I would say, you know, kind of we would consider something maybe a little bit smaller than kind of the historical deal sizes that we've done, maybe down in the $15 million EBITDA range, so dipping a little bit lower with a more of a build strategy. But other than that, we're remaining, you know, very disciplined in what our criteria are.
spk06: Fair enough. I appreciate the call. Thanks, Celeste.
spk02: Thank you. One moment while we prepare for the next question. And the next question that we have is coming from Matt Corenda of Roth Capital. Your line is open.
spk07: Thanks for taking the questions. Maybe just sticking on the deal front for a second. I'm just curious. It sounds like a little bit of a tone shift from you guys in terms of just a little bit more awareness on a slowing or softening economy, especially on the industrial side of things. Does that change your posture toward or appetite for larger acquisitions going forward here? And maybe, Elias, if you just unpack your commentary around deals not meeting your standards, it sounds like it may be more quality of deal flow, but maybe just curious if you could talk a little bit about pricing expectations and sort of if you could unpack that theme as well, that'd be helpful.
spk05: Yeah, sure. I mean, you know, Matt, it feels like the economy is weakening, and we clearly factored that into our expectations in the back half, and that's why we didn't raise, notwithstanding having a really good quarter and feeling really good about the business. But that obviously factors into how we're looking at companies right now, too, in that there's probably going to be some reduced expectation of growth at a minimum or maybe even, you know, they don't grow at all as the economy feels like it's raining in a little bit. So that impacts our view of forward earnings, which is going to impact our view on, you know, kind of valuation. And that may or may not allow for us to be competitive because we have maybe a slightly more negative view of kind of how the economy is unfolding right now. I would say in terms of multiples, you know, we expect to pay more elevated multiples. And if you think of the businesses that we've acquired recently, you know, Primaloft and BOA, you know, as two examples, those are companies that traded, you know, kind of in mid-double-digit range, you know, kind of 15-ish times. And these are incredibly high-quality businesses with really deep economic modes. And those are the kind of businesses that we're looking for. I mean, we want source of real innovation. We want, you know, protected IP or some go-to-market strategy that we can feel really good about as being durable. And ultimately, it needs to manifest in the company being able to significantly outgrow its underlying industry. And so those are sort of the criteria that we're evaluating here. And this has been part of our, you know, sort of strategic sort of, you know, kind of not shift, but as our capital costs have come down, we've been talking to you about buying faster growing businesses and more well protected. Those two things have gone hand in hand. And so that is what we are looking for, and we're very strict about meeting that criteria. And I would just say whether, you know, you're today or a year ago or you're back in 21 when times were really robust or 19, those companies always trade for strong multiples because when you identify companies with those characteristics, it's typically about, you know, you have to pay the clearing price for those, and, you know, those are really in-demand assets. You know, when we look back historically at our performance, notwithstanding they're our highest-priced assets, they're also our best-performing assets on return on invested capital as well. So, you know, that's sort of where we see the deal market right now, and volume has come back, but as you said, quality is still lagging.
spk07: Okay. Very helpful. And then just curious, maybe on the balance sheet front, like if we're a little bit more reticent about the economy, why not focus on reducing that leverage? I know that you already are starting to do so. And you mentioned that without a deal, I guess, we just naturally sort of de-lever over the next couple of quarters. But maybe we could talk about the trajectory there where we might expect to end the year on that leverage. if we didn't see a deal and maybe would that be a priority of ours? Like if we, if we kind of see things softening a bit.
spk09: Yeah, Matt, this is Ryan. Thanks for the question. You know, you're, you're right in that our leverage is continuing to come down and you heard us on the past few calls, you know, talk about that post the honeypot transaction, you know, we're seeing some continued really strong performance at our consumer subsidiaries, which is growing the denominator there. So as we, you know, build our business, our leverage is coming down, came down from little above 3.8 down to about 3.7 this quarter. I'd expect, you know, kind of similar declines over the next two quarters as we, you know, not only grow the EBITDA line, but we start to, you know, cash convert some of our other subsidiaries, inventory and such. So, you know, still the focus of ours, I'd say it's more organic. You know, I think what you also saw during the quarter is we raised a little bit of preferred. So, you know, I think that's been a good source of, you know, some equity capital for us to deleverage. But I do think we feel confident in our growth prospects for this year. You know, clearly we're guiding to, you know, north of 12% growth in EBITDA year over year. So I think that all, you know, feels good. So I think we're in good shape on the balance sheet as I think about closing out the year.
spk07: Okay, great. And if I could just do one more on one of the fundamental businesses. So on Lugano, wanted to hear if you guys had any sort of preliminary learnings you could share from the London Salon opening. Like if you have quantifiable metrics, that's great, but just any learnings around that and how that sort of informs the additional expansion plans you may have for the rest of Europe. And also, I guess I noticed that the incrementals there just continue to be really strong and it's It's kind of hard to model this thing given you're punching above 40% in terms of incrementals. How sustainable is that? Sort of how should we think about modeling that going forward? I would assume you're probably going to try to tamp us down on that front, but it was impressive. So I just wanted to hear a little bit more on that.
spk10: Sure. I mean, the company does a great job. You said some of the learnings. that we take from London, the company does a great job of sort of seeding the market with a lot of deep relationships before they enter a market. And they did the same thing here in London. We had a, a smaller business working with European equestrian customers that we spent some time with and that helped us see this market when we went into London. So that would be point one. Point number two would be that our sort of – the way we do business, which is sort of deep relationships and good value on really amazing product, works over there as well. And so there was some sort of, you know – you work with a buyer who buys differently, work with customers who purchase differently. We're learning that it works there as well. And we're optimistic that there are several more, at least European locations that it could work to. So it only made us more bullish on sort of growth internationally and growth within Europe. As far as the growth, I'm not gonna make your modeling exercise any easier. I'm sorry, Matt. I think we're gonna continue to see really robust growth in 2024 and into 2025. And the robustness of that beyond that, you know, will somewhat be determined by the number of salons we open and somewhat just be driven by, you know, continued growth at the company and continued depth of relationships.
spk07: Got it. Any rule of thumb around inventory investment, translating the sort of sales? I think you guys have provided some metrics around that. I'd be curious if you have another crack at that one or if I had an exchange on that front.
spk05: Yeah, man, it's basically remained similar to where it's been. I would say we do have some additional investment we're making up front as our growth rate is actually accelerating, which is really remarkable given how fast this business has been growing. But as it's accelerating, it actually requires a little bit more upfront capital, especially as we're expanding our footprint. And for example, going to London, now being international, it creates some challenges about moving inventory that kind of required a little bit more investment. So in general, I would say the numbers are sticking exactly where they have been historically. And As we look at the business, I mean, you know, part of the question that Pat said on your – or answer Pat did for your question on modeling, I mean, the level of inventory investment also is a, you know, kind of component to modeling out how large and fast this business will grow. We've said this for three years, and I know it's hard, you know, for everybody and for us, too, to accept a little bit that as we put in more inventory and There is, you know, kind of demand within our network. And as we're growing that network of buyers, there's additional demand that is there. And so we are creating more revenue opportunity with inventory investments. I think that continues and that has not slowed down. And so as we look into 2025, other than a desire to be a little bit more conservative and not get out over our skis, I would say there's nothing present right now that says this business should have a material change and sort of you know, kind of its performance and growth outlook, it's going to be the, you know, kind of same thing, getting the people, you know, onboarded, getting, you know, kind of the product and the inventory, you know, built. You know, those are sort of some of the constraints right now that we have to growth. It feels like demand still is, you know, solidly more within our network than what we're currently satisfying.
spk08: Okay. Fair enough. I appreciate all the detail there, guys. I'll jump back in queue.
spk02: Thank you. And one moment for the next question. Our next question will be coming from the line of Derek Somers of Jefferies. Your line is open.
spk08: Hey, good afternoon, everyone. A couple of quick questions on the subsidiaries. Just on Honeypot and Lugano, could you remind us if there's any sort of seasonality we should be cognizant of in modeling those. And then additionally, any kind of commentary on the 5.11 business transition or transformation would be helpful as well.
spk10: What was the second part? So 5.11. So seasonality at Honeypot, I mean, it's lessening. I think Q1 tends to be a pretty strong quarter for them. But other than that, there's not too much seasonality. At Lugano, I think we've tended to see sort of Q4 and Q1 be bigger than Q2 and Q3. And it just depends on the year. As it relates to the 5-11 transition, you know, we're spending a lot of time working on sort of opening up the aperture for 5-11. And how do we how do we bring in more customers to this product that just performs incredibly well and has an incredibly trusted and authentic brand? And so we're spending a lot of time understanding just how we do that, and that's been a big part of our focus over the last sort of two to three months and will be for the next three to four months. What also is happening, though, at the same time is, You know, inventory fluctuations still related to COVID where you'll purchase too much or too little is impacting our retail sales somewhat in VTC. And then lastly, as I touched on with PFAS, you know, we have a lot of different SKUs that we now need to bring in PFAS-free product for, and it's a relatively complex process. Different states – different agencies in different states and different – consumer wholesale customers will demand different specs. Some will want PFAS products, some will not. So you essentially have to keep a double inventory on a lot of products and that's presenting us with some, um, um, some operational challenges. I think we're going faster than most in the industry. And so I think it could potentially be a tailwind when we get through it in 2025, but it is, uh, it's a bit of a headwind right now.
spk08: Got it. Thank you. And then, um, Just on the interest rate cuts, you know, it will flow through on your variable rate debt at the corporate level, but is there any kind of interest rate exposure we should be aware of at the subsidiary level?
spk09: No, Derek. All that subsidiary debt is owed us, so there's no, you know, exogenous risk outstanding with respect to interest rate risk. Any cut would be a positive to the business.
spk08: Got it. Thank you for the call. All right.
spk02: Thank you. As a reminder, if you would like to ask a question, please press star 1-1 on your telephone. Our next question will be coming from Robert Dodd of Raymond James. Your line is open.
spk03: Hi, guys. Sorry about the background noise. It feels kind of like beating a dead horse after my questions the last few quarters, but Lugano. So a couple of quarters ago, I asked you if you thought it could hit a third of Tony Bidar this year? And you said, no, well, it's a third this quarter. Obviously, that's not a guarantee that it's going to keep growing as a share, but the discussion point is, I mean, again, the concentration issue, it's a great business, but it is such a big driver of your growth and a big consumer of cash. I think it was, Ryan said, what, $71 million? in operating cash flow consumption in the first half. So, you know, to fund the accelerating growth, you know, you talked about it last quarter, but I mean, can you give us an update on what your thoughts are on how you can continue to maximize the performance and the returns at Logano while not having it just dominate all the you know, all the financial needs of the platform.
spk05: Yeah, I mean, Robert, it's, you know, we talked about this last time. It's kind of a high-class problem because the return on invested capital is so, you know, abnormally high here. From a capital allocation standpoint, it's really hard to ignore the request for additional capital because we can't direct it, you know, in an alternative matter and get a better return. And so I think that leads us to want to continue to fund this, notwithstanding the risk that you're highlighting, which is it's becoming more concentrated in the portfolio. And it is like any hyper-growth business that has a capital need to it. It is a capital consumer while it's in this massive growth phase. I mean, if this thing slowed down to a 20% growth business – it would be a really good growth, you know, cash flow producer. And if it grew at 3% or 4%, it would produce a ton of free cash flow. You know, it just is happening to grow at 40%, 50%. And that causes, you know, our capital, the capital requirements to be quite substantial. I think it really is, you know, kind of strategically how we think about the asset. I think funding its needs, as long as it is a, you know, kind of subsidiary of us, is important, and it is important to the value creation of Cody, and it's important to Lugano reaching its maximum value potential as well. So, I think, you know, there isn't really an alternative to fund the capital that, you know, they can wisely put to work with these type of returns and Clearly, if that breakdown in return on invested capital happens, then everything gets reevaluated. But if you say that that's sort of a status quo, then, you know, we will continue to fund that. You know, I think what it points to is, given the differential in growth rate, and it is growing so much faster than the rest of the portfolio, The third, you know, 33% concentration it represented in the quarter is likely only going to grow if that, you know, differential continues, which we would expect it to. And so in the next couple of years, it's going to become a bigger part of Cody unless, you know, we do something creatively with it. And I would say that could be, you know, anything from, you know, a divestiture, which, you know, clearly that is part of our strategy. And we've done that historically with our assets to, you know, kind of continuing to own it and financing it in. you know, a more creative way. And I can think of like, you know, Fox as an example of how we owned a business and creatively financed it through taking part of it public and then having, you know, its own access to capital markets or debt markets, wherever it could, you know, participate. And that was a win-win because it lowered their cost of capital. We still owned a big piece. So as the majority owner in the beginning, you know, kind of was an overall way that it was a overall reduction in our whack by continuing to own a majority of that business. So there's, you know, some options that we have. And by the way, I just point to two things we've done in the past. We're thinking about a plethora of options of financing and ways, you know, in this business over the next couple of years to both manage risk, And obviously get the best return for our shareholders. But, you know, suffice to say, it is top of mind for us as well. And we recognize the high class problem that has come from a company that is growing this rapidly and now represents, you know, kind of a big cap or a big concentration with such a large capital need.
spk03: Kind of understood, and it is really a higher class problem. So, kind of tied to that, I mean, you talk about the healthcare that you might be considering doing, you know, a more built strategy, are you making a smaller acquisition? Obviously, if you had done something larger on healthcare, or hypothetical, obviously, that would actually reduce the Lugano concentration. So, if your aim is something smaller in healthcare, when, if you enter that, does that actually accelerate the need to find a solution. I mean, Lugano is not a problem, right? But to find some kind of creative way to manage the diversification if healthcare is going to hypothetically be a smaller add-on than might have been the case you thought a year ago.
spk05: Sure. And that's sort of door number three that also exists, which is We do enough acquisitions. You've identified health care, but that's only one of the three verticals that we invest in. So it could be another consumer business. It could be another, you know, industrial tech business that we're looking at or, you know, just broadly. I mean, the teams are out, you know, day in and day out. Robert looking aggressively for acquisition candidates. And as we are starting to see some green shoes, I think there are opportunities that are going to come about to deploy capital. That clearly is a, you know, something that will diversify Lugano, diversify Cody more and bring Lugano's concentration down. So that's the third way we can do it. Clearly balancing there is the leverage. And so, you know, kind of access to capital markets becomes important. There's a lot of factors that are in it, but I wouldn't focus too much on the fact that we're, maybe looking at some smaller healthcare deals. We're also looking at healthcare deals that are larger. It just so happens that in that vertical, we would start slightly smaller than where we will in our industrial and our consumer verticals. But we would just be just as happy to do a $500 million deal in the healthcare market as we do in a consumer or an industrial. But if we're, do a $200 million deal we will start there as well. And that was sort of the only point I was making earlier. But, yes, we are looking to acquire and do so prudently without overusing, you know, kind of leverage on our balance sheet. So, you know, we're walking that fine line.
spk02: Got it. Thank you. Thank you. One moment for the next question. And our next question will be coming from Matthew P. Howlett of B. Riley. Your line is open.
spk01: Hey, guys. Thanks for taking my question. Just to be clear, I think you said last call that you'd be comfortable taking leverage of half return, three-quarters return temporarily. Do you still feel the same if you found something that you really wanted?
spk05: Yes. And I would say, Matt, given BOA and Primaloft and their return to growth, I mean, these are just really outstanding businesses. And, you know, we kind of I think all went through a traumatic period where, you know, inventory destocking was kind of a generational thing. Nobody anticipated the events that COVID would unleash, including, you know, sometimes sell-in being half of what sell-through is. And it really had to reset all of our expectations lower for a period of time. But these are great businesses that have good industries with growth, and they are taking share, and they are really well protected. And so even if the macro economy weakens a little bit here or there, those businesses can grow right on through it. And they've proven the ability to do that in normal times where inventory changes aren't so wild. And so we look at Lugano, which is, frankly, totally disconnected to the macro economy, unless there's another great financial event that occurs. I mean, this is a company that deals with a clientele that is very unique, And it is a very disruptive business in a massive industry that they've got a tiny amount of share. So it's a really good formula to be able to grow outside of general macro economic conditions. And so, you know, as we said before, you look at those three businesses, And they are poised to grow not only now, but in 25 and beyond. It's just such a good stable base that you can get comfortable with to then take on a little bit more balance sheet leverage and be comfortable with that. So, you know, maybe a long-winded answer of saying, yes, we remain, you know, confident for the right asset that we could take leverage up a half to three-quarters of a term.
spk01: That's incredible that you have that loyalty, that consumer loyalty that gives you gives you that much confidence. So it's really, they really are special companies. So on that note, I mean, just, you talked about, you know, new products at the Honeypot and looking at 2025, you talked about maybe new, some new technology at Velocity, new products at Honeypot, anything, can you go into a little more detail on what could happen? What could, the impact could be on 25? And is there anything else, any new, anything else in the other subsidiaries to flag in 25? Just when you think about 25, something stopped being rolled out in the subsidiaries. Anything that highlights
spk05: Yeah, I would just say, in general, all of our companies are working on, I mean, we, you know, work really closely with our businesses, and everybody has product roadmaps. new product introductions that are coming out and how we're going to execute and be more profitable. We give you a little bit of a preview quarterly, and we talk about some of the highlights in our businesses. But, you know, I could just tell you that across all of our consumer businesses, They are all working on innovative products to roll out. In our industrial businesses, we're trying to figure out how to, you know, again, continue to innovate. Can we become more efficient? Can we lower our cost and deliver better value to our customer and capture some of that for ourselves? Can we create new solutions that are environmentally friendly and differentiated? You know, it would be too much to go into detail in all of our companies, but I can tell you our, you know, kind of driving, you know, daily mission in our company and when we come in every day and what we talk to our companies about is what are you doing to maintain your source of innovation and competitive lead over our competition that's out there. And they focus on this on a daily basis. It's a tone that's set at the top. It starts with me. It goes through Pat and everybody at Compass and down through all of our portfolio companies. So, you know, I will tell you the innovation engine is stronger within our organization today than it's ever been. And that's why we feel that, you know, we're poised to not only meet but, you know, potentially exceed here our core growth rates over the next few years. Disconnected. from the global economy because we just put up nearly 20% growth, and one of our industrial businesses had a really difficult quarter. You know, that's a tough thing to do. We have some great businesses that are driving that, and that gives us a lot of really good, you know, hope, and not only hope, visibility into 25 and beyond that this company is, you know, set up to really have these kind of growth rates for an extended period of time.
spk01: I have to tell you, it's an incredibly strong statement. I really appreciate the confidence with the outlook. I guess just to throw in, I mean, on the honeypot, that was growing at – you bought at an incredible rate. I know it ran into a little bit of a speed bump, but you still feel that – I think that was growing at like a 52% K. I mean, it was something incredible. You still feel like it's a double-digit grower long-term or a double-digit grower?
spk10: Yes, I feel like it's a double-digit or it's a double-digit grower long-term, and I think we'll get back on that trajectory. The brand is authentic, and they're really trying to destigmatize any issues around feminine care, and there is a real mission-driven aspect to them that we respect and we think the market and customers will reward.
spk05: And, you know, Matt, it's not unusual. And the first integration period when we, you know, buy a company, there's a lot that these guys have to go through to become part of the Cody family. And, you know, as we Codyize a company, as we say internally, you know, the first part of that is there's a lot of reporting and other obligations that, you consume a lot of resources. We have to make some investments there. And before you start to get the benefit of some of the productivity that results from that, you're starting to have the resource drain and the cost that go in. So it is not abnormal for us to have, you know, a period where growth is a little bit slower and then to see that start to accelerate, especially as we get more of an infrastructure built in a lot of the companies that we partner with, you know, for long-term growth, and that starts to manifest. And we would expect, by putting more investment in, that their growth rates, you know, can pick up from where they were. Now, Honeypot was such a small company. Its growth rate is the law of large numbers or, I guess, the reverse here. So it was coming off such a small base. You know, you're not going to get a 40%, 50% growth rate. Right. But, you know, we're putting in a lot of infrastructure investment right now so that this company can be a double-digit grower consistently under our ownership. And given its, you know, innovative products, given the TAM that it has, given its current market share, and given the, you know, strength of the brand and perception from its consumer, there is nothing that suggests that it can't, you know, kind of be a double-digit grower for an extended period of time.
spk01: Thanks for clarifying everything. Thank you.
spk02: Thank you. Thank you. There are no more questions at this time. I would like to go ahead and turn the call back over to Mr. Elias. Please go ahead.
spk05: Thank you, Operator. As always, I'd like to thank everyone again for joining us on today's call and for your continued interest in COTI. Thank you for your support.
spk02: This does conclude today's conference call for today. Thank you so much for joining. You may disconnect.
Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-